ClinicalTrials.gg
CompletedNCT04907877ProCOVIDUpdated Mar 22, 2023

Bifido- and Lactobacilli in Symptomatic Adult COVID-19 Outpatients

An interventional study of Probiotic and Placebo in COVID-19 Respiratory Infection, sponsored by Nordic Biotic Sp. z o.o.. Completed at 3 sites in Ukraine. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-03-22.

Sponsored by Nordic Biotic Sp. z o.o. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in COVID-19 with a site in Ukraine — 1 open to participants now, 1 under way, 1 of them phase 3. COVID-19 · Ukraine.

Enrollment
34th of 39
70 · median 285
Started
2021
with 22 others
No phase
2 of 45
none open now
Registered
28th of 45
by date

Among the 45 studies in COVID-19 with a site in Ukraine, this one is the 34th largest by enrollment of the 39 interventional ones that give a count, is one of 23 that started in 2021, is one of 2 with no phase, and was the 28th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 45 studies in COVID-19 with a site in Ukraine is open now. Recruiting first, the newest first:

A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in COVID-19 with a site in Ukraine, or all of them as a file.
02

Study summary

There is evidence that some types of probiotics play a role in alleviation of symptoms of acute respiratory tract infections and bursting immune response to respiratory and enteric viruses. Available data serves a rationale for the study exploring a role of nutritional support with probiotics in adult outpatients with COVID-19. Hypothesis of the study is that a proposed mixture of lactobacilli and bifidobacteria facilitate faster recovery from COVID-19 and enhance specific immune response to SARS-CoV-2 antigens.

Read the detailed description

One hundred adults with confirmed (PCR or antigen test) symptomatic COVID-19 lasting upto 5 days will be screened for the study. When the subject meets enrollment criteria, he/she will be randomized to take an investigational product (probiotic, test dietary supplement, TDS), a mixture of lactobacilli and bifidobacteria or placebo 1 time a day before breakfast for 28 days after enrollment. During observation, the patient will keep Respiratory Illness Diary. Blood serum will be collected at baseline, day 0-5 (Nurse Visit 1), after 28-35 days (Nurse visit 2), and 6 months (Nurse visit 3) for evaluation of anti-SARS-CoV-2 antibodies to nucleocapsid and spike antigents. In 3 months, investigator/family physician will collect Post-COVID-19 Questionnaire

03

Conditions studied

  • COVID-19 Respiratory Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 - ≤ 65 years;
  2. Male or non-pregnant female;
  3. Informed virtual pre-consent and paper signed consent forms;
  4. Confirmed symptomatic COVID-19 lasting 0-5 days;
  5. Subject understands and agrees to comply with study procedures including triple blood analysis for anti-SARS-CoV-2 IgG;

Exclusion criteria

Exclusion Criteria:

  1. Risk for the complicated course of COVID-19 due to:

    1.1. Hypertension; 1.2. Diabetes mellitus; 1.3. conditions; 1.4. Chronic pathology of the respiratory system ; 1.5. Chronic pathology of the cardiovascular system ; 1.6. Malignant tumor ; 1.7. Systemic inflammatory connective tissue disease ; 1.8. Cerebrovascular disease ; 1.9. Chronic hepatitis. Hepatic cirrhosis; 1.10. Inflammatory bowel diseases ; 1.11. Chronic kidney disease ;

  2. Drug or alcohol abuse as suspected by investigator;
  3. History of persistent diarrhea of any cause;
  4. Use of pre- or probiotics during the last 2 weeks before enrollment;
  5. Allergy to any components of the TDS;
  6. Technical difficulties to perform virtual study visits.
  7. Inability to perform a blood test for antibodies after 6 months
  8. Inability to swallow capsules, or choking / coughing while eating
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Probiotic

    NordBiotic ImmunoVir, a mixute of bidido- and lactobacteria administered in a dose of 5 billion once a day for 28 days

    Dietary Supplement: Probiotic

  • Placebo comparator
    Placebo

    Maltodextrine administered once a day for 28 days

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementProbiotic

    Probiotic will be taken 1 time a day before breakfast for 28 days.

  • Dietary supplementPlacebo

    Placebo will be taken 1 time a day before breakfast for 28 days.

06

What researchers measure

Primary outcomes

  1. Global symptom score

    Clinical score of Coronavirus disease-19; minimal score 0 (healthy), maximal score 36 (worst disease)

    Time frame: 10 days

Secondary outcomes

  1. 8 - point ordinal severity scale of coronavirus disease-19

    World Health Organization scale; score 0 - healthy, score 8 - death

    Time frame: 28 days

  2. Time to recovery

    Day when patient symptom score is 0

    Time frame: 28 days

  3. Percent of completely recovered patients

    Patients with symptom score is 0

    Time frame: 28 days

  4. Hospitalization rate

    Percent hospitalized due to COVID-19

    Time frame: 28 days

Other outcomes

  1. Anti-SARS-CoV-2 antibodies IgG response

    Antibody titer to NCP and spike antigen

    Time frame: Days 0-5, day 28-35, month 6th

07

Study locations

3 sites
  • Hemo Medica Ukraine Ltd
    Uzhhorod, Zakarpatska 88000, Ukraine
  • Lviv State Center for Disease Control and Prevention
    Lviv, 79014, Ukraine
  • 3rd City Clinical Hospital of Lviv
    Lviv, 79016, Ukraine
08

References and documents

Publications

  • Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, Li P, Hu B, Wang J, Hu C, Jin Y, Niu X, Ping R, Du Y, Li T, Xu G, Hu Q, Tu L. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020 May;115(5):766-773. doi: 10.14309/ajg.0000000000000620. PubMed 32287140 ↗
  • Smyk W, Janik MK, Portincasa P, Milkiewicz P, Lammert F, Krawczyk M. COVID-19: Focus on the lungs but do not forget the gastrointestinal tract. Eur J Clin Invest. 2020 Sep;50(9):e13276. doi: 10.1111/eci.13276. Epub 2020 Jul 5. PubMed 32406522 ↗
  • Westermann C, Gleinser M, Corr SC, Riedel CU. A Critical Evaluation of Bifidobacterial Adhesion to the Host Tissue. Front Microbiol. 2016 Aug 5;7:1220. doi: 10.3389/fmicb.2016.01220. eCollection 2016. PubMed 27547201 ↗
  • Van Tassell ML, Miller MJ. Lactobacillus adhesion to mucus. Nutrients. 2011 May;3(5):613-36. doi: 10.3390/nu3050613. Epub 2011 May 20. PubMed 22254114 ↗
  • Olaimat AN, Aolymat I, Al-Holy M, Ayyash M, Abu Ghoush M, Al-Nabulsi AA, Osaili T, Apostolopoulos V, Liu SQ, Shah NP. The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19. NPJ Sci Food. 2020 Oct 5;4:17. doi: 10.1038/s41538-020-00078-9. eCollection 2020. PubMed 33083549 ↗
  • Yeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, Chung AC, Cheung CP, Tso EY, Fung KS, Chan V, Ling L, Joynt G, Hui DS, Chow KM, Ng SSS, Li TC, Ng RW, Yip TC, Wong GL, Chan FK, Wong CK, Chan PK, Ng SC. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021 Apr;70(4):698-706. doi: 10.1136/gutjnl-2020-323020. Epub 2021 Jan 11. PubMed 33431578 ↗
  • Chai W, Burwinkel M, Wang Z, Palissa C, Esch B, Twardziok S, Rieger J, Wrede P, Schmidt MF. Antiviral effects of a probiotic Enterococcus faecium strain against transmissible gastroenteritis coronavirus. Arch Virol. 2013 Apr;158(4):799-807. doi: 10.1007/s00705-012-1543-0. Epub 2012 Nov 28. PubMed 23188495 ↗
  • Miettinen M, Pietila TE, Kekkonen RA, Kankainen M, Latvala S, Pirhonen J, Osterlund P, Korpela R, Julkunen I. Nonpathogenic Lactobacillus rhamnosus activates the inflammasome and antiviral responses in human macrophages. Gut Microbes. 2012 Nov-Dec;3(6):510-22. doi: 10.4161/gmic.21736. Epub 2012 Aug 16. PubMed 22895087 ↗
  • Nakayama Y, Moriya T, Sakai F, Ikeda N, Shiozaki T, Hosoya T, Nakagawa H, Miyazaki T. Oral administration of Lactobacillus gasseri SBT2055 is effective for preventing influenza in mice. Sci Rep. 2014 Apr 10;4:4638. doi: 10.1038/srep04638. PubMed 24717726 ↗
  • Gao X, Huang L, Zhu L, Mou C, Hou Q, Yu Q. Inhibition of H9N2 Virus Invasion into Dendritic Cells by the S-Layer Protein from L. acidophilus ATCC 4356. Front Cell Infect Microbiol. 2016 Oct 25;6:137. doi: 10.3389/fcimb.2016.00137. eCollection 2016. PubMed 27826541 ↗
  • Vouloumanou EK, Makris GC, Karageorgopoulos DE, Falagas ME. Probiotics for the prevention of respiratory tract infections: a systematic review. Int J Antimicrob Agents. 2009 Sep;34(3):197.e1-10. doi: 10.1016/j.ijantimicag.2008.11.005. Epub 2009 Jan 28. PubMed 19179052 ↗
  • Zimmermann P, Curtis N. The influence of probiotics on vaccine responses - A systematic review. Vaccine. 2018 Jan 4;36(2):207-213. doi: 10.1016/j.vaccine.2017.08.069. Epub 2017 Sep 18. PubMed 28923425 ↗

Individual participant data

Plan to share: No — Not applicable as not decided yet

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Dec 2022, 12 months.

Of 138 industry-sponsored interventional studies with no phase under COVID-19, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 12 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2021
First posted
Jun 1, 2021
StartActual
Dec 1, 2021
Primary completionActual
Dec 1, 2022
CompletionActual
Mar 1, 2023
Last update
Mar 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04907877
Lead sponsor
Nordic Biotic Sp. z o.o.
Responsible party
Sergei Gerasymov, MD, PhD (Principal Investigator, Nordic Biotic Sp. z o.o.) — Principal investigator
First posted
Jun 1, 2021
Start date
Dec 1, 2021
Primary completion
Dec 1, 2022
Completion
Mar 1, 2023
Last update
Mar 22, 2023

Study contacts

Zoriana Hoda, MD
study director · Lviv State Laboratory Center, Ministry of Health of Ukraine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion